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Abstract
Chemokine receptor antagonists appear to access two distinct binding sites on
different members of this receptor family. One class of CCR4 antagonists has
been suggested to bind to a site accessible from the cytoplasm while a second
class did not bind to this site. In this report, we demonstrate that antagonists
representing a variety of structural classes bind to two distinct allosteric sites on
CCR4. The effects of pairs of low-molecular weight and/or chemokine CCR4
antagonists were evaluated on CCL17- and CCL22-induced responses of human
CCR4+ T cells. This provided an initial grouping of the antagonists into sets
which appeared to bind to distinct binding sites. Binding studies were then per-
formed with radioligands from each set to confirm these groupings. Some novel
receptor theory was developed to allow the interpretation of the effects of the
antagonist combinations. The theory indicates that, generally, the concentra-
tion-ratio of a pair of competing allosteric modulators is maximally the sum of
their individual effects while that of two modulators acting at different sites is
likely to be greater than their sum. The low-molecular weight antagonists could
be grouped into two sets on the basis of the functional and binding experi-
ments. The antagonistic chemokines formed a third set whose behaviour was
consistent with that of simple competitive antagonists. These studies indicate
that there are two allosteric regulatory sites on CCR4.
Abbreviations
CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CXCL, CXC-chemokine
ligand; CXCR, CXC-chemokine receptor; DMSO, dimethylsulphoxide; DR, concen-
tration ratio; F-actin, filamentous actin; NSB, non-specific binding; PBMC, periph-
eral blood mononuclear cells; SPA, scintillation proximity assay.
Introduction
The chemokines are a family of small (predominantly
8–10 kDa) proteins which act as leucocyte chemoattractants.
They may be subdivided into four families based on the
arrangement of the first two of four conserved cysteine
residues. The largest of these families are the CC-chemo-
kines in which the cysteine residues are adjacent and the
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CXC-chemokines in which the cysteines are separated by
an intervening amino acid residue (Zlotnik and Yoshie
2000). The chemokine receptors are Gi-protein coupled
receptors and are also divided into four families, based
on their ligand specificity, for example CC-chemokines
are agonists for CC-chemokine receptors while CXC-
chemokine receptors respond only to CXC-chemokines
(Murphy et al. 2000).
CCR4 is the receptor for the CC-chemokines
CC-chemokine ligand (CCL) 17 (previously known as
thymus and activation-related chemokine, TARC) and
CCL22 (or macrophage-derived chemokine, MDC;
chemokine and receptor nomenclature follows Alexander
et al. 2011). It has also been reported that CCR4 is a
receptor for chemokine-like factor 1, an immune cell
chemoattractant which is not a member of the chemokine
family (Wang et al. 2006). CCR4 is found on a number
of cells of the haematopoietic lineage, for example T cells,
platelets (Clemetson et al. 2000), and mast cells (Jure-
malm et al. 2002). The expression on T cells is restricted
to specific subsets as CCR4 has been reported to be
expressed on CD25+ regulatory T cells (Iellem et al.
2001), skin-homing (cutaneous lymphocyte antigen+) T
cells (Campbell et al. 1999) and TH2 and TH17 but not
TH1 helper T cells (Bonecchi et al. 1998; Lim et al. 2008).
The expression of CCR4 on TH2 cells has prompted some
interest in it as a therapeutic target for asthma and other
allergic diseases as the cytokines produced by these cells
(interleukins 4, 5, 9, and 13) are thought to induce the
pathological changes associated with these diseases
(Larche et al. 2003). Indeed, CCR4+ T cells have been
shown to be elevated at the sites of inflammation in a
number of allergic diseases (Panina-Boudignon et al.
2001; Nouri-Aria et al. 2002) and numbers are further
increased after allergen challenge (Panina-Boudignon
et al. 2001). There are also a number of studies in human
disease which have shown that CCL17 and CCL22 are ele-
vated in plasma, serum or at sites of inflammation in
patients with a number of allergic or eosinophilic condi-
tions (Lezcano-Meza et al. 2003; Jahnz-Rozyk et al. 2005)
and that the levels are correlated with disease severity.
Several classes of low-molecular weight antagonist of
CCR4 have now been identified (Purandare and Somer-
ville 2006) and it has recently been reported that at least
one of these classes of antagonist may act at an intracel-
lular binding site on CCR4 (Andrews et al. 2008) and
must therefore act as allosteric modulators of this recep-
tor. However, in the same study it was clear that the
Bristol-Myers Squibb antagonist (compound 5 in Fig. 1)
did not bind to this binding site. In this report, we dem-
onstrate that the interactions of a range of CCR4 antago-
nists (see Fig. 1 and Table 1), are consistent with the
presence of two distinct binding sites for low-molecular
weight antagonists on CCR4 and that both of these sites
are distinct from the binding site for chemokines sug-
gesting that CCR4 has three spatially distinct ligand-
binding sites. Some theory required for the interpretation
of the antagonist interaction studies is developed in the
Appendix.
Materials and Methods
Chemokine-stimulated increases in cellular
F-actin content
Blood was taken from normal volunteers who had taken
no medication within the previous 10 days and chemoki-
ne-induced increases in the filamentous (F)-actin content
of CD4+ CCR4+ T cells were measured as previously
described (Slack and Hall 2012). Briefly, the peripheral
blood mononuclear cells (PBMC) were isolated and
stained with fluorescein isothiocyanate-conjugated anti-
human CD4 and phycoerythrin-conjugated anti-CCR4
antibodies. The cells were then incubated with antagonist
or vehicle (0.1% dimethylsulphoxide [DMSO]) for
30 min at 37°C before stimulation with agonist for
15 sec. The assay was terminated by addition of 3% form-
aldehyde. The fixed cells were stained with Alexa fluor-
647 phalloidin and the mean fluorescence intensity of
1000 CD4+ CCR4+ cells per sample was determined. This
was expressed as a fraction of the mean intensity of the
CD4+ CCR4 cells in the same sample.
Acquisition of the blood samples was approved by the
Hertfordshire Research Ethics Committee and all donors
gave informed consent prior to donation.
Cell culture and membrane preparation
Chinese hamster ovary (CHO)-K1 cells expressing CCR4
under Geneticin selection (CHO-CCR4) were grown in a
95% O2/5% CO2 atmosphere in Dulbecco’s modified
eagle medium F12 nutrient mix containing 5% heat-
inactivated dialysed foetal bovine serum, 2 mmolL1
L-gln, and 0.5 mgmL1 Geneticin. Membranes were pre-
pared from the CHO-CCR4 cells as previously described
(Slack and Hall 2012).
Radioligand binding
[125I]CCL-17 binding studies
Inhibition of the binding of [125I]CCL-17 to CHO-
CCR4 membranes was determined using a scintillation
proximity assay (SPA) as previously described (Slack and
Hall 2012). To allow quantification of the number of
binding sites, saturation binding experiments were also
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performed by filtration. These studies were performed
with 20 lgmL1 membrane protein at room tempera-
ture (20–22°C) in SPA-binding buffer (20 mmolL1
HEPES, 100 mmolL1 NaCl, 10 mmolL1 MgCl2,
10 lgmL1 saponin, 0.1% bovine serum albumin (BSA)
adjusted to pH 7.4 with KOH) in a total volume of
500 lL. Non-specific binding (NSB) was determined in
the presence of 10 nmolL1 CCL22. Plates were
incubated with gentle agitation for 2 h and the reaction
terminated by rapid filtration on a Brandel harvester
(Brandel Inc. Gaithersburg, MD) through GF/C filter
papers presoaked in 0.3% polyethylenimine. Samples
were washed three times with ice-cold 0.5 molL1 NaCl
solution and filters allowed to dry before the amount of
bound radioligand was measured using a Packard Cobra
II Gamma Counter (PerkinElmer LAS UK Ltd., Beacons-
field, UK). All experiments were performed in the
presence of 1% DMSO.
Figure 1. Chemical structures of the low-molecular weight CCR4 antagonists used in this study.
ª 2013 GSK group of companies. All rights reserved. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2013 | Vol. 1 | Iss. 2 | e00019
Page 3
R. J. Slack et al. Three Antagonist Binding Sites on CCR4
[3H]antagonist binding studies
[3H]antagonist binding experiments were performed as
previously described (Slack et al. 2011) with minor modi-
fications. Assays were performed at room temperature
(20–22°C) in SPA binding buffer, without BSA, incuba-
tion was done for 2 h in a total volume of 1.4 mL.
Saturation binding experiments contained 14 lgmL1
membrane protein, while inhibition experiments were
performed at 50 lgmL1 protein. NSB was determined
in the presence of 10 lmolL1 of the unlabelled com-
pound. Inhibition curves were constructed in the presence
of approximately 1 nmolL1 [3H]5 or approximately
0.7 nmolL1 [3H]8. Binding was terminated by filtration
on a Brandel harvester through GF/B filter papers
presoaked in 0.3% v/v polyethylenimine ([3H]5) or water
([3H]8). Filters were washed three times with ice-cold
distilled water. The amount of radioligand bound was
measured by liquid scintillation spectroscopy, in Ultima-
FloTMM (PerkinElmer LAS UK Ltd.), using a TriCarb
2900 TR liquid scintillation counter (PerkinElmer LAS
UK Ltd). All experiments were performed in the presence
of 1% DMSO.
Materials
All cell culture media and reagents were purchased from
Gibco (Invitrogen Ltd., Paisley, UK). DMSO was obtained
from Fisher Scientific UK Ltd. (Loughborough, UK). All
other chemicals were purchased from Sigma-Aldrich Co.
Ltd. (Gillingham, UK) unless otherwise stated. Chemokines
were obtained from R&D systems (Abingdon, UK), Pepro-
tech (London, UK) or ALMAC (Craigavon, UK) (CCL22).
[125I]CCL-17 (specific activity 2200 Ci mmol1) were
obtained from PerkinElmer LAS UK Ltd. [3H]5 and [3H]8
(specific activity 37 and 53 Ci mmol1 respectively) were
synthesized by GE Healthcare UK Ltd. (Little Chalfont,
UK). Small molecule antagonists were synthesized by
Respiratory CEDD Medicinal Chemistry, GlaxoSmithKline.
Data analysis
Concentration-response curves were fitted with a Hill
function of the form
E ¼ Emax½A
nH
ECnH50 þ ½AnH
þ Basal
where, [A] is the agonist concentration, E is the
response to that concentration of agonist, Emax is the
maximal response to the agonist, Basal is the level of
activity in the absence of agonist and nH is the Hill
coefficient.
To quantify the effects of antagonists in the func-
tional assays, concentration-ratios (DR) were estimated.
In cases where the antagonist caused a change in the
maximal response, the DR was calculated at the
response level corresponding to half the maximal
response in the presence of the antagonist (this is justi-
fied in the Appendix). When the effect of a combination
of antagonists was investigated, the concentration-ratio
was calculated at half of the maximal response for the
curve with the lowest maximal response of the set (see
Appendix).
Binding inhibition curves were fitted with a Hill func-
tion of the following form
B ¼ B0  Imax½I
nH
ICnH50 þ ½InH
where, [I] is the inhibitor concentration, B is the level
of binding in the presence of that concentration of
inhibitor, Imax is the maximal level of inhibition of
binding, B0 is the level of radioligand binding in the
absence of the inhibitor and nH is the Hill coefficient.
Where inhibitors reduced the binding to a level which
wasn’t significantly different from NSB, the affinity (Ki)
was determined using the Cheng-Prusoff correction
(Cheng and Prusoff 1973; Leff and Dougall 1993).
Where specific binding was only partially inhibited and
data quality allowed, the interaction was assumed to be
allosteric and the data were fitted with the following
equation (Ehlert 1988)
B ¼ Bmax½A
Ka
Kiþ½I
Kiþ½I=a
 
þ ½A
where, A is the radioligand, I is the inhibitor, Ka is the
dissociation constant of the radioligand, Ki is the dissocia-
tion constant of the inhibitor and a is the binding coo-
perativity constant.
Table 1. The sources of the low-molecular weight antagonists used
in this study.
Compound Source patent
1 US7144903B2 (Amgen)
2 WO2010097395A1 (GSK)
3 WO2010097395A1 (GSK)
4 WO2004020584A2 (Bristol-Myers-Squibb)
5 WO2004020584A2 (Bristol-Myers-Squibb)
6 WO2007111227A1 (Astellas)
7 WO2003051870A1 (Astra Zeneca)
8 WO2003059893A1 (Astra Zeneca)
9 US20060004010A1 (Ono)
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Results
CCL17 and CCL22 induced concentration-dependent
increases in the F-actin content of human CD4+ CCR4+
cells. The pEC50 of CCL17 was 9.97  0.02 (n = 69) and
that of CCL22 was 9.99  0.04 (n = 17) (Fig. 2A). The
effects of the low-molecular weight antagonists on the
increase in F-actin content of the T cells induced by
CCL17 are summarized in Figure 2B,C, and Table 2. The
effects of the antagonistic chemokines are shown in Fig-
ure 2D. Compounds 6, 7, and 8 caused a small but
statistically significant decrease in the F-actin content of
the cells (P < 0.05, paired t-test) while the other low-
molecular weight antagonists had no significant effect.
CCL11 and CCL223-69 were also without effect on the
F-actin content of the cells. With the exception of com-
pound 3, all of the low molecular weight antagonists
significantly changed the maximal response to CCL17
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Figure 2. Effects of the antagonists on increases in the F-actin content of human CD4+ CCR4+ T cells. (A) The effects of CCL22 and CCL17
alone. (B) The effects of CCL17 alone (ctrl) or in the presence of 3 lmolL1 1, 10 lmolL1 2, 1 lmolL1 3 or 300 nmolL1 4. (C) The effects
of CCL17 alone (ctrl) or in the presence of 30 nmolL1 5, 100 nmolL1 6, 3 lmolL1 7, 300 nmolL1 8 or 100 nmolL1 9. (D) The effects of
CCL17 alone (ctrl) or in the presence of 1 lmolL1 CCL11, or 300 nmolL1 CCL223-69. Data are the mean of the replicate determinations (as
specified in Table 2 or the text) and vertical bars show the SEM. Curves show the Hill function generated from the mean of the fit parameters.
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(P values are noted in Table 2). Compounds 4, 5, 6, 8,
and 9 were insurmountable while compounds 1, 2, and 7
increased the maximal response to this agonist (for
contrast, in the remainder of the text this phenomenon
will be referred to as suprasurmountability), although the
effect of compound 1 was relatively small compared with
that of the other two compounds. The antagonistic
chemokines had no significant effect on the maximal
response to CCL17.
As an initial approach to determining the minimum
number of binding sites available to CCR4 antagonists,
we determined the effects of combinations of the antago-
nists on CCL17-induced increases in CD4+ CCR4+ cell
F-actin content. The effects of coincubation with
compounds 1 and 2 are shown in Figure 3A. The DR of the
combination (49.0 [22.9, 105], n = 4) was much greater
than the sum of the DRs of the two antagonists alone
(13.7) and close to their product (45.9). A similar pattern
of behaviour was observed on coincubation with com-
pounds 1 and 7 (Fig. 3B). However, in this case, the DR of
the combination (90.0 [65.5, 124], n = 4) was greater than
the product of the individual DRs (49.8). The sum was
14.7. Interestingly, coincubation of CCL17 with 2 and 7
(Fig. 3C) resulted in a DR of 10.8 (5.6, 21.0) (n = 3),
which was similar to the sum of their individual DRs (14.0)
and markedly less than their product (46.2).
This suggests that 1 binds to a site distinct from that
to which 2 and 7 bind but that 2 and 7 may bind to a
common site (see Appendix 1). Hence, we examined the
interactions of these compounds with the other antago-
nists to explore their binding site specificity. The interac-
tions of the other low-molecular weight antagonists with
compounds 1 and 2 are summarized in Table 3. Coincu-
bation with compound 1 gave a DR greater than the sum
of the individual DRs with compounds 3, 8, and 9 while
coincubation of these compounds with compound 2
resulted in DRs close to the sum of the individual DRs.
The converse was true of compounds 4 and 5 whose
effects approximately summated with compound 1 and
were greater than additive with those of compound 2.
Interestingly, compound 6 had an approximately additive
interaction with both 1 and 2. Coincubation of CCL223-69
with either 1 or 2 resulted in a DR which was greater
than the sum of the DRs for the individual antagonists
and this was also true of coincubation of CCL11 with 1.
This is also summarized in Table 3. Coincubation of the
cells with CCL223-69 and CCL11 resulted in a DR (12.4
[4.2, 36.3], n = 3) which was very close to the sum of the
DRs of the individual antagonists (13.9, product 36.2).
No formal statistical analysis was performed on the
interaction data as the statistical distribution of the sum
of two DRs or its logarithm is not known. The effects of
the combinations of antagonists on the maximal response
to CCL17 are summarized in Table 4. Figures illustrating
the effects of coincubation of cells with 1 or 2 and the
other antagonists are provided in the Supporting
information.
The effect of the combination of compounds 1
(3 lmolL1) and 2 (10 lmolL1) was also determined on
CCL22-induced increases in CD4+ CCR4+ T cells
(Fig. 3D). Coincubation with the two antagonists caused a
shift in the CCL22 concentration-response curve (DR =
35.5 [28.0, 45.0], n = 3) that was much greater than the
sum of the individual DRs (10.6). Indeed, in this case it was
somewhat larger than the product of the DRs (27.8). In
contrast to their effects on CCL17, neither compound alone
nor their combination had a significant effect on the
response to high concentrations of CCL22. Also, 1, 4, 5, 6,
7, and 8 (at the concentrations tested against CCL17) had
no effect on increases in the F-actin content of this T-cell
Table 2. The effects of the antagonists on CCL17-induced increases in the F-actin content of human CD4+ CCR4+ T cells when used alone.
Treatment (n) Concentration pEC50 Basal Maximum Log(slope) Log(DR
1) % Inhibition2
Control (69) – 9.97  0.02 1.00  0.01 1.94  0.03 0.17  0.01 – –
1 (42) 3 l molL1 8.99  0.04 1.00  0.02 1.99  0.03 0.10  0.01 0.97  0.03 3.5  1.4*
2 (32) 10 l molL1 9.11  0.06 0.98  0.02 1.96  0.04 0.00  0.02 0.80  0.04 8.9  2.8**
3 (3) 1 l molL1 8.79  0.22 1.00  0.04 1.96  0.07 0.12  0.05 1.16  0.26 5.3  10.8
4 (21) 300 n molL1 9.03  0.09 0.97  0.02 1.55  0.04 0.05  0.02 1.12  0.06 38.4  2.2***
5 (19) 30 n molL1 9.26  0.09 0.97  0.02 1.50  0.05 0.01  0.02 0.96  0.06 42.1  2.3***
6 (14) 100 n molL1 9.65  0.06 1.00  0.02 1.69  0.06 0.10  0.02 0.61  0.05 31.0  1.9***
7 (15) 3 l molL1 9.14  0.05 0.99  0.02 2.11  0.07 0.03  0.02 0.81  0.03 15.1  2.7***
8 (27) 300 n molL1 9.07  0.07 0.99  0.02 1.61  0.04 0.06  0.03 1.19  0.06 40.3  2.0***
9 (9) 100 n molL1 8.98  0.13 0.93  0.02 1.36  0.03 0.08  0.03 1.23  0.07 49.4  2.4***
CCL11 (7) 1 l molL1 9.29  0.05 1.02  0.07 1.90  0.10 0.17  0.04 0.64  0.07 2.8  3.7
CCL223-69 (9) 100 n molL1 8.92  0.06 1.07  0.04 1.97  0.07 0.15  0.03 0.91  0.07 2.1  4.9
1Concentration-ratio: calculated relative to the response at the midpoint of the curve in the presence of the inhibitor.
2Percentage inhibition of the maximal response to CCL17.
*P < 0.02, **P < 0.005, ***P < 104 (Student’s t-test).
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population in response to CXCL12, an agonist of CXCR4,
in cells from two donors (data not shown).
Binding site interactions were further explored in radioli-
gand binding assays. In saturation binding experiments,
[125I]CCL17 bound to CHO-CCR4 membranes with affin-
ity 0.15 nmolL1 (pKD = 9.82  0.06, n = 4). The satu-
rating amount of specific binding was 0.73  0.06 pmol
per mg membrane protein. [3H]5 bound with affinity
1.4 nmolL1 (pKD = 8.87  0.06, n = 3) and, at satura-
tion, labelled 10.0  2.8 pmol of binding sites per mg pro-
tein while [3H]8 bound with affinity 0.28 nmolL1
(pKD = 9.56  0.08, n = 3) and labelled 11.0  1.0 pmol
binding sites per mg protein at saturation. The number of
binding sites labelled by the two tritiated antagonists was
not significantly different (Student’s t-test). None of the
radioligands showed a measurable level of specific binding
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Figure 3. The effects of combinations of antagonists on chemokine-induced increases in the F-actin content of human CD4+ CCR4+ T cells. (A)
The effects of CCL17 alone (ctrl) or in the presence of 3 lmolL1 1, 10 lmolL1 2 or 1 and 2 at these concentrations. (B) The effects of CCL17
alone (ctrl) or in the presence of 3 lmolL1 1, 3 lmolL1 7 or 1 and 7 at these concentrations. (C) The effects of CCL17 alone (ctrl) or in the
presence of 10 lmolL1 2, 3 lmolL1 7 or 2 and 7 at these concentrations. (D) The effects of CCL22 alone (ctrl) or in the presence of
3 lmolL1 1, 10 lmolL1 2 or 1 and 2 at these concentrations. Data are the mean of the replicate determinations (as specified in Table 3 or
the text) and vertical bars show the SEM. Continuous curves shown the Hill function generated from the mean of the fit parameters. The dashed
curves show the expected position of a concentration-response curve shifted by the sum of the DRs of the two antagonists.
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Table 3. The effects of combinations of compounds 1 or 2 and the other antagonists on CCL17-induced increases in the F-actin content of
human CD4+ CCR4+ T cells.
Compound1 DR2 ipo 1 Sum Product DR2 ipo 2 Sum Product
3 (3, 3) 91.1 (10.5, 790) 18.7 86.2 18.3 (5.4, 62.5) 22.4 113
4 (4, 5) 19.0 (8.6, 42.0) 19.6 95.8 30.2 (11.4, 79.9) 16.2 57.5
5 (3, 4) 12.8 (4.2, 38.7) 10.8 28.8 27.8 (15.7, 49.4) 18.4 37.9
6 (4, 3) 13.5 (8.7, 21) 13.3 37.6 14.0 (5.0, 38.9) 10.0 24.7
8 (3, 3) 83.7 (20.3, 566) 20.8 108 11.3 (6.4, 19.9) 17.7 73.5
9 (5, 5) 183.9 (91.2, 372) 24.1 146 21.1 (9.2, 48.6) 21.2 73.1
CCL11: 1 (4) 25.1 (8.5, 73.9) 10.0 24.8 ND ND ND
CCL223-69 (4, 5) 67.7 (46.3, 99.0) 17.3 73.6 23.4 (13.2, 41.4) 12.4 37.8
ND, not determined.
1Concentrations were the same as stated in Table 2. Numbers in parentheses are the number of replicates for the determinations in the presence
of 1 then 2.
2Values in parentheses after the DRs show the 95% confidence interval.
Table 4. The effects of combinations of compounds 1 or 2 and the other antagonists on the maximal increase in the F-actin content of human
CD4+ CCR4+ T cells in response to CCL17.
Compound1 i.p.o. 1 Alone2 12 i.p.o. 2 Alone2 22
3 (3, 3) 36.5  7.1 5.3  10.8 6.2  5.2 3.6  3.1 5.3  10.8 8.6  4.7
4 (4, 5) 17.6  2.1 37.5  13.4 4.4  3.6 31.1  5.1 36.6  3.6 0.7  3.5
5 (3, 4) 22.8  6.5 36.0  3.4 2.5  1.0 49.6  4.9 54.9  1.5 2.5  2.4
6 (4, 3) 4.1  2.5 28.9  1.7 0.1  2.2 2.4  10.3 33.8  3.2 29.4  9.9
7 (4, 3) 19.2  5.5 16.0  1.6 4.1  3.5 34.3  10.6 33.2  4.2 29.8  9.7
8 (3, 3) 49.5  6.1 40.5  1.3 1.5  3.1 9.7  2.9 42.5  4.2 17.6  5.0
9 (5, 5) 68.1  4.1 49.3  3.6 8.8  1.9 32.9  8.2 49.3  3.6 0.7  3.5
CCL11: 1 (4) 8.9  2.8 1.7  2.5 3.2  5.2 ND ND ND
CCL223-69 (4, 5) 1.7  3.4 7.3  7.1 2.7  4.2 0.5  3.7 9.7  5.1 0.9  11.7
ND, not determined.
1Concentrations were the same as stated in Table 2. Numbers in parentheses are the number of replicates for the determinations in the presence
of 1 then 2.
2The mean and sem of the percentage inhibition of the maximal response to CCL17 in the presence of the antagonists determined in the same
experiments as the effects of their combination.
Table 5. The binding affinities and cooperativity factor (a) values for unlabelled antagonists and chemokines against [125I]CCL17, [3H]compound
5 and [3H]compound 8 in CHO CCR4 membranes. Data are the mean  SEM of at least three separate determinations with 95% confidence lim-
its shown in parentheses where appropriate.
Radioligand [125I]CCL17 [3H]compound 5 [3H]compound 8
Compound pKi a pKi pKi
1 6.34  0.07 – 6.21  0.06 <6.00
2 7.74  0.41 – ND 8.26  0.05
3 8.21  0.141 0.14 (0.09, 0.21) ND 8.22  0.01
4 8.56  0.08 – 8.76  0.06 ND
5 9.10  0.09 – 9.14  0.03 ND
6 8.70  0.21 – 8.66  0.05 ND
7 7.53  0.05 – ND 7.56  0.04
8 9.04  0.171 0.03 (0.02, 0.04) ND 9.19  0.04
9 8.74  0.091 0.03 (0.02, 0.05) ND 8.73  0.07
CCL17 9.64  0.10 – ND ND
CCL22 10.2  0.05 – ND ND
CCL223-69 8.17  0.09 – ND ND
CCL11 6.17  0.06 – ND ND
ND: Ehlert equation not fitted due to poor definition of the individual inhibition curves.
1Data derived from fitting the equation of Ehlert (1988).
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to membranes from CHO-K1 cells which had not been
transfected with CCR4.
The binding of [125I]CCL17 was inhibited to a level
which was not significantly different from NSB by all
of the chemokines and all of the low-molecular weight
antagonists except 3, 8, and 9 (Fig. 4, summarized in
Table 5). These three compounds caused a maximum
of 84.9  0.7%, 93.1  1.9%, and 90.5  3.0% inhibi-
tion, respectively, and were analysed assuming an allo-
steric interaction. When effects on the binding of [3H]5
or [3H]8 were determined (Figs. 5A,B and 6A,B,
Table 5), the low molecular weight antagonists clearly
fell into two groups: those which displaced [3H]5 to its
NSB but only partially inhibited [3H]8, if at all, (4, 5,
and 6) and those which did the converse (2, 3, 7, 8,
and 9). Compound 1 was of limited solubility under
the conditions of the tritiated antagonist binding assays,
precipitating at concentrations above 1 lmolL1. It was
not, therefore, possible to generate complete inhibition
curves for this compound. However, lower concentra-
tions of 1 did inhibit the binding of [3H]5 while they
did not inhibit the binding of [3H]8 (indeed there may
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Figure 4. Inhibition of [125I]CCL17 binding to membranes from CHO-CCR4 cells by: (A) CCL22, 1, 4, 5 or 6; (B) CCL22, 2, 3, 7, 8 or 9; (C)
CCL22, CCL17, CCL223-69 or CCL11. Data are the mean of at least three separate determinations and vertical bars show the SEM. Curves show
the Hill function generated from the mean of the fit parameters.
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have been an increase in the binding). The chemokines
had only limited effects on the binding of either triti-
ated ligand (Figs. 5C and 6C, Table 5). Indeed, the
antagonistic chemokines had no effect at concentrations
below 1 lmolL1.
Discussion
In this report, we have studied interactions between
CCR4 antagonists to investigate the number of binding
sites on the receptor. To enable the interpretation of the
functional experiments, theory was developed to describe
the effects of combinations of allosteric modulators on
the response to an agonist (Appendix). The key results of
this analysis are that the DRs caused by two allosteric
modulators that act at the same site are, generally, maxi-
mally additive while those of two modulators acting at
distinct sites are likely to be supraadditive. These results
are analogous to those describing the interaction of two
competitive antagonists (Paton and Rang 1965) and an
allosteric and competitive antagonist (Christopoulos and
Mitchelson 1994), respectively. However, our treatment
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Figure 5. Inhibition of [3H]5 binding to membranes from CHO-CCR4 cells by: (A) 1, 4, 5 or 6; (B) 2, 3, 7, 8 or 9; (C) CCL22, CCL17, CCL223-69
or CCL11. Data are the mean of three separate determinations and vertical bars show the SEM. Curves show the Hill function generated from
the mean of the fit parameters.
2013 | Vol. 1 | Iss. 2 | e00019
Page 10
ª 2013 GSK group of companies. All rights reserved. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Three Antagonist Binding Sites on CCR4 R. J. Slack et al.
considered ligands which are not simply neutral antago-
nists at the allosteric site and this can modify the behav-
iour. For example, perfect multiplicativity can only result
if at least one of the modulators is surmountable and at
most one is an agonist. Furthermore, a surmountable
modulator can “protect” the receptors from the effects of
an insurmountable compound on the maximal response.
This provides another diagnostic criterion for a noncom-
petitive interaction between modulators as any pair for
which this protection is not observed must bind to dis-
tinct sites.
In the actin polymerization assays, CCL11 and
CCL223-69 behaved as simple surmountable antagonists,
consistent with them acting competitively. Of the small
molecule antagonists, 4, 5, 6, 8, and 9 were insur-
mountable while 1, 2, and 7 were suprasurmountable.
Insurmountability has two frequent explanations: non-
competitive inhibition or a pseudo-irreversible competi-
tive interaction. Given the rather short agonist contact
time in the assay the latter cannot be dismissed outright.
Suprasurmountability cannot be the result of a purely
competitive interaction. Allosteric ligands can increase
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Figure 6. Inhibition of [3H]8 binding to membranes from CHO-CCR4 cells by: (A) 1, 4, 5 or 6; (B) 2, 3, 7, 8 or 9; (C) CCL22, CCL17, CCL223-69
or CCL11. Data are the mean of three separate determinations and vertical bars show the SEM. Curves show the Hill function generated from
the mean of the fit parameters.
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the maximal response to an agonist (e.g., Hall (2000))
but this could also be due to an interaction further
down the signal transduction cascade. However, neither
1 nor 7 had any effect on the response to CXCL12, an
agonist of the related receptor CXCR4, which is also
Gi-coupled (Murphy et al. 2000), suggesting an effect at
the level of CCR4.
The small molecule antagonists could be classified into
two groups based on their interaction profiles: those which
interacted supraadditively with 1 and (sub) additively with
N
H
N
OH
(CH2)5
NH
O Cl
Cl
74
(A)
(C) (D)
(E) (F)
(B)
Figure 7. A comparison of selected representative chemokine ligands demonstrating the pharmacophore features of two apparently distinct classes
of small molecule. The CCR4 compounds studied here (4, 7) are compared with literature examples of the CCR5 antagonist maraviroc (A), CCR2
antagonists (B–D) and CXCR1–2 compounds (E, F). Lipophilic features are highlighted in green, basic centres in blue, and acidic features in red.
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2 and those which did the converse. This suggests that there
are two small molecule antagonist binding sites on CCR4,
one which binds 1, 4, and 5 (site 1) and one which binds 2,
3, 7, 8, and 9 (site 2). The binding site of 6 is ambiguous as it
had an approximately additive interaction with both 1 and
2. CCL11 and CCL223-69 showed a third profile as their
effects were supraadditive with both 1 and 2 but additive
with each other indicating an additional binding site for
these ligands. Strictly, given the caveats noted in the
Appendix, these data are consistent with aminimum of three
binding sites. Strong negative-binding cooperativity is indis-
tinguishable from competition and hence an additive inter-
action can also occur when ligands bind to distinct sites.
To test this hypothesis and to further probe the binding
site of 6, radioligand binding experiments were performed
with representative small molecule radioligands: [3H]5 for
site 1 and [3H]8 for site 2. We also examined effects on
[125I]CCL17 binding. In CHO-CCR4 cell membranes, all of
the ligands inhibited the binding of [125I]CCL17 suggesting
they do indeed interact with CCR4. Again, the small mole-
cule antagonists divided into two groups: those which inhib-
ited the binding of [3H]5 to NSB but only partially inhibited
the binding of [3H]8 (4 and 6) and those which did the
converse (2, 3, 7, 8, and 9). It was not possible to define a
complete inhibition curve for 1 due to its poor solubility
under the conditions of the tritiated ligand-binding assays.
However, at the concentrations tested, it inhibited the bind-
ing of [3H]5 but not that of [3H]8 confirming that 1 binds
to site 1. Thus, using two probes which differ from those in
the functional studies, the compounds partitioned into the
same two sets. This provides further evidence that there are
only two binding sites available to bind these compounds as
the alternative hypothesis would be quite complex.
CCL11 and CCL223-69 had limited effects on the bind-
ing of either tritiated antagonist suggesting that they bind
to neither of their binding sites. However, they did inhibit
[125I]CCL17 binding, suggesting that they bind to CCR4.
CCL11 has previously been shown to increase the migra-
tion of CCR4-transfected 300-19 cells in response to
CCL22 (Sebastiani et al. 2005). This was suggested to
result from binding of CCL11 to CCL22 rather than from
an interaction via the receptor. However, in our hands
CCL11 behaved as a surmountable antagonist of CCL22
and CCL17 in actin polymerization assays (Nalesso et al.
2008; Fig. 2D) and inhibited the binding of [125I]CCL17.
Although these effects could still be due to an interaction
with the chemokines, it is noteworthy that, in Sebastiani
et al., CXCL10, and by inference CCL11, did not affect
the binding of [125I]CCL22. Thus, in our hands, the
behaviour of CCL11 is more consistent with that of a
simple competitive antagonist. This does not exclude the
possibility that CCL11 also binds to CCL17 but this inter-
action is not apparent under our assay conditions.
One discrepancy noted by Andrews et al. and con-
firmed in this study was an apparent lack of reciprocity
between the effects of the small molecule antagonists on
the binding of [125I]CCL17 and those of CCL17 on the
binding of the small molecules. In Andrews et al., the
chemokine had no effect on the binding of the antagonist
radioligand. In this report there was a clear inhibitory
effect of CCL17 on [3H]8 and of CCL22 on [3H]5 bind-
ing, however, in both cases, the inhibition was partial and
occurred at concentrations much higher than those
required to inhibit the binding of [125I]CCL17. This is in
contrast to close agreement of the affinities obtained for 5
and 8 in [125I]CCL17 and antagonist binding experi-
ments. However, this apparent lack of reciprocity is not
inconsistent with the ternary complex model of G-protein
activation (De Lean et al. 1980; Appendix). In particular,
if an allosteric ligand has no binding cooperativity with
the agonist but is an inverse agonist or has negative acti-
vation cooperativity, then the ligands only interact when
bound to receptor:G-protein (RG) complexes. If RG com-
plexes represent a small proportion of the receptors (and
[125I]CCL17 labelled approximately 7% as many sites as
the tritiated antagonists), the effect of the agonist on
labelled antagonist binding may simply not be detectable.
If there is binding cooperativity, the midpoint of the ago-
nist inhibition curve will be closer to the affinity for free
receptors than that for the RG complex.
As both tritiated antagonists labelled a similar number
of binding sites and only bound to membranes from cells
transfected with CCR4 both binding sites appear to be
present on CCR4. Andrews et al. (2008) showed that 7
and related compounds bound to a site on the intracellu-
lar surface of CCR4. Hence, site 2 must correspond to
this site. This site binds to aryl sulphonamides and hence
to acidic ligands. It is not clear where site 1 resides on
the receptor. However, the compounds which bind to this
site are all bases. Interestingly, it has been shown that a
conserved glutamic acid residue in the seventh transmem-
brane domain of chemokine receptors (E290 in CCR4) is
involved in antagonist binding (Berkhout et al. 2003;
Rosenkilde and Schwartz 2006; Wise et al. 2007). It is,
therefore, tempting to speculate that site 1 on CCR4
involves this residue. Wherever it is located, it must be an
allosteric site given the similarity between the ability of
the chemokines to inhibit binding of [3H]5 and [3H]8
and the interaction of CCL223-69 with 1 and 2. Thus,
there appear to be two allosteric sites on CCR4. Hence,
the insurmountability of compounds 4, 5, 6, 8, and 9 is
consistent with negative activation cooperativity with
CCL17. Indeed, the effects of strictly surmountable allo-
steric antagonists (i.e., those that only affect orthosteric
ligand affinity) cannot become insurmountable when the
system does not reach steady state: a finite change in the
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kinetic constants cannot affect a ligand’s ability to satu-
rate the receptors at some finite concentration.
Chemically, the compounds studied here fall into two
fundamental classes: the site 1 compounds feature a large
lipophilic moiety some distance from a basic centre (as
illustrated in Fig. 7); the site 2 compounds are aryl sulph-
onamides. The former general pharmacophore is well rep-
resented among small molecule chemokine antagonists, in
particular the CCR5 antagonist maraviroc (A) and a
number of CCR2 compounds, for example B (Xia and
Sui 2009) and D (Berkhout et al. 2003). Aryl sulphona-
mides are also found among CCR2 antagonists from
Chemocentryx (C) and GlaxoSmithKline (see Xia and Sui
2009) so it is interesting to speculate that CCR2 may have
two analogous binding sites.
A characteristic property of the biaryl sulphonamide
core is its acidity. It is noteworthy that an acidic biaryl
motif has also been described in the putative intracellular
antagonists of CXCR1 and CXCR2, for example E (Nich-
olls et al. 2008) and F (Salchow et al. 2010). Thus, it is
further tempting to propose that these general pharmaco-
phores describe the characteristics required of a small
molecule to bind to, respectively, the transmembrane and
intracellular sites which may be common in several
chemokine receptors.
In summary, the use of antagonist interaction and
radioligand binding experiments demonstrates that there
are three sites on CCR4 at which antagonists can act, the
orthosteric site and two allosteric sites.
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on increases in the F-actin content of human CD4+
CCR4+ T cells in response to CCL17.
Appendix: Effects of combinations
of allosteric modulators on responses
to an orthosteric agonist
Expressions for the DR of the combination of two com-
petitive antagonists and the combination of a competitive
and an allosteric antagonist have previously been derived
(Paton and Rang 1965; Christopoulos and Mitchelson
1994). However, to aid interpretation of the data pre-
sented in this report, expressions for the effects of the
combination of two allosteric modulators are required. In
this case, there are two possibilities: competition between
the allosteric ligands at the same site and binding of the
allosteric ligands to distinct binding sites. The required
expressions are derived below using the recently published
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model of Slack and Hall (2012) as their basis. It should
be noted that, as some of the antagonists considered here
affect the maximal response to the agonist, this phenome-
non has been included in the models. The situations
under consideration are shown schematically in Fig-
ure A1. For those who prefer not to wade through the
mathematical justification, the key results can be stated as
follows: the DR of the combination of two allosteric
modulators acting at the same site on a receptor is maxi-
mally the sum of the individual DRs whilewhile that of
two modulators acting at different sites should be greater
than the sum of the individual DRs. There are some
caveats to these statements (particularly when the mod-
ulators exhibit negative binding cooperativity with each
other) but this provides a useful rule of thumb for
interpreting the effects of combinations of allosteric
modulators.
An operational model of the effects
of an allosteric ligand
Prior to considering the effects of combinations of modu-
lators, a novel operational model of the effects of a single
allosteric modulator will be derived. This model includes
constitutive receptor activity and the possibility that the
allosteric modulator is an agonist or inverse agonist in its
own right. In the presence of a single allosteric modula-
tor, the systems shown in Figure A1A,B both reduce to
that shown in Figure A1C. The properties of this model
and its applicability to experimental data have been dis-
cussed in detail elsewhere (Hall 2013). However, some
complementary details of the derivation and behaviour of
the model are presented below to prime the discussion of
the models where two allosteric modulators are present.
In this scheme, the equilibrium concentration of the free
receptor is given by:
½R ¼ ½RT
1þ ½BKb þ
½A
Ka
1þ ½BaKb
 
where, Ka and Kb are the equilibrium dissociation
constants of A and B, respectively, and a is the binding
cooperativity constant (Hall 2006). The concentrations of
the other receptor species can be obtained from this
expression by multiplying [R]T in the numerator by:
[A]/Ka for [AR]; [B]/Kb for [RB]; or [A][B]/aKaKb for
[ARB]. The pharmacological stimulus, S, is given
by S = [R] + eA[AR] + eB[RB] + eAB[ARB], where the
(A) (B)
(c)
Figure A1. (A) Reaction scheme for a system in which two allosteric modulators (B and C) compete at a common site to modulate the effects of
an orthosteric ligand (A). (B) Reaction scheme for a system in which two allosteric modulators bind to distinct sites to modulate the effects of an
orthosteric ligand. (C) Reaction scheme for a system in which a single allosteric modulator interacts with an orthosteric ligand.
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various e factors represent the intrinsic efficacies of the
ligands or combinations of ligands indicated by the sub-
scripts (and quantify how effectively they activate the sig-
nal transduction pathway relative to the free receptor).
Let the response, E, be given by
E ¼ EmaxS
n
Kne þ Sn
¼ Emax ½R þ eA½AR þ eB½RB þ eAB½ARBð Þ
n
Kne þ ½R þ eA½AR þ eB½RB þ eAB½ARBð Þn
¼
Emax½RnT 1þ eB½BKb þ
eA½A
Ka
1þ eAB½BeAaKb
  n
Kne 1þ ½BKb þ
½A
Ka
1þ ½BaKb
  n
þ½RnT 1þ eB½BKb þ
eA½A
Ka
1þ eAB ½BeAaKb
  n
¼
Emaxvn 1þ eB½BKb þ
eA½A
Ka
1þ eAB½BeAaKb
  n
1þ ½BKb þ
½A
Ka
1þ ½BaKb
  n
þvn 1þ eB½BKb þ
eA½A
Ka
1þ eAB½BeAaKb
  n
(A1)
where, v = [R]T/Ke. In this formulation of the model, the
“activation cooperativity” of the ligands is given by eAB/
eAeB. Equating the response to equieffective concentra-
tions of the orthosteric ligand in the presence and absence
of the allosteric modulator gives the following
Emaxvn 1þ eA½AKa
 n
1þ ½AKa
 n
þvn 1þ eA½AKa
 n
¼
Emaxvn 1þ eB ½BKb þ
eA½A0
Ka
1þ eAB½BeAaKb
  n
1þ ½BKb þ
½A0
Ka
1þ ½BaKb
  n
þvn 1þ eB½BKb þ
eA½A0
Ka
1þ eAB½BeAaKb
  n
Some straight-forward but rather unwieldy algebra then
gives the following expression for the DR caused by the
modulator.
DR ¼
1þ ½BKb
eAeB
eA1 þ
Ka
½A
1eB
eA1
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
  (A2)
The following aspects of this expression are noteworthy.
First, as expected, the use of the null method has elimi-
nated the contribution from the signal transduction system
– no terms relating to the transducer function (v or n)
occur in equation (A2). However, the effects of the alloste-
ric modulator do depend on the pharmacological proper-
ties of the orthosteric ligand – Ka and eA occur in (A2).
Indeed, this is also true for the analogous expression for a
competing ligand (which can, for example, be derived by
letting a ? ∞ and eAB = eA in (A2) and is, in fact, its
numerator). An important special case of (A2) occurs
when eB = 1 and eAB = eA (i.e., when the two ligands only
affect each other’s binding affinity and the allosteric ligand
is a neutral antagonist at the allosteric site). In this case,
equation (A2) simplifies to the following
DR ¼
1þ ½BKb
eA1
eA1þ
Ka
½A
11
eA1
 
1þ ½BaKb
eA1
eA1þ
½A
Ka
eAeA
eA1
  ¼ 1þ ½BKb
1þ ½BaKb
which is (a rearrangement of) the expression derived by
Ehlert (1988) with the same assumptions.
The terms in [A] in equation (A2) are a consequence
of the fact that the concentration-response curves are not
parallel when the allosteric ligand has an effect in the
absence of A or affects its maximal response (as illustrated
in Figure A2). When eB 6¼ 1, the allosteric ligand is an
agonist or inverse agonist in its own right. In this case, at
low orthosteric ligand concentrations, the term in Ka/[A]
contributes significantly to the DR. There are then con-
centrations of A for which the concentration-response
curve in the presence of a negative allosteric modulator
which is an agonist, for example, lie to the left instead of
the right of the control curve (the curves cross), resulting
in concentration-ratios less than unity in this region. The
concentration-ratio can also take negative values. The lat-
ter is clearly physically meaningless but, rather than sug-
gesting a flaw in the model, simply reflects the fact that
equation (A2) is not mathematically restricted to positive
ligand concentrations. Negative concentration-ratios
indicate that the one of the curves under comparison can
only attain the specified level of response at a negative
concentration of A. When eΑB 6¼ eA, the allosteric ligand
changes the maximal response to A. In this case, the term
in [A]/Ka becomes important when [A] is large and
causes similar behaviour of the DR (changes in sense and
negative values).
The previous paragraph essentially considers the behav-
iour of the DR near the asymptotes of the concentration-
response curves. However, there will often be a range of
orthosteric agonist concentrations over which the concen-
tration-response curves in the presence and absence of
allosteric ligand are approximately parallel. In this case,
the expression for the concentration-ratio simplifies to
the following
DR ¼
1þ ½BKb
eAeB
eA1
 
1þ ½BaKb
eAB1
eA1
 
(see Hall 2013) which shows that, in this range of or-
thosteric ligand concentrations, a DR can be usefully
determined (a brief exploration suggests that a good rule
of thumb is to estimate the DR at the half-maximal
response level of the most inhibited curve in a set unless
this is not possible). Within this range, the concentration
of the allosteric modulator which causes a DR of 2 is as
follows
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½BDR¼2 ¼
aeAKb
a eA  eBð Þ  2 eAB  1ð Þ
and the maximal dose-ratio is
DRmax ¼ a eA  eBð ÞeAB  1
Both of these expressions depend on the intrinsic
efficacy of the orthosteric ligand, showing that, even
with identical cooperativity constants, there is the
potential for a systematic difference between orthosteric
ligands in the apparent pA2 of and maximal shift
caused by an allosteric modulator. These expressions
do, however, become independent of eA when eA ≫ eB
and eAB  eA > 1, in other words when the modulator
is an inverse agonist and/or its effects on the asymp-
totes of the concentration-response curve to the orthos-
teric ligand are small. Under these conditions, these
expressions simplify to those of an “affinity-only” mod-
ulator, that is [B]DR=2 = aKb/(a – 2) and DRmax = a. In
this case, the data can be analysed using the null meth-
ods described by Ehlert (1988).
Having established that it is meaningful to define a
DR for an allosteric modulator which affects the asymptote
(s) of the concentration-response curve to an orthosteric
agonist, at least in some circumstances, the effects of
combinations of allosteric modulators will be inves-
tigated.
A model of the effects of two allosteric
ligands which bind to the same allosteric
site
The binding reaction underlying the model shown in Fig-
ure A1A describes the binding of two allosteric modula-
tors to the same site on a receptor in the presence of an
orthosteric ligand. In this scheme, the equilibrium con-
centration of the free receptor is given by:
½R ¼ ½RT
1þ ½BKb þ
½C
Kc
þ ½AKa 1þ
½B
aKb
þ ½CbKc
 
where, Ka, Kb, and Kc are the equilibrium dissociation
constants of A, B, and C, respectively, and a and b
are the binding cooperativity constants of A with B and C
respectively (Hall 2006). The concentrations of the other
receptor species can be obtained from this expression by
multiplying [R]T in the numerator by: [A]/Ka for [AR];
[B]/Kb for [RB]; [C]/Kc for [RC]; [A][B]/aKaKb for
[ARB]; or [A][C]/bKaKc for [ARC]. By analogy with the
E/
E m
ax
0
0.5
1.0
0
0.5
1.0
a b c
[A]
b c d
10410–3 10–2 10010–1 102101 103 10310–4 10–3 10010–2 10–1 101 102
[A]
(A) (B)
Figure A2. Regions of different DR behaviour according to equation (A2). Concentration-response curves were simulated using equation (A2). In
each case [B] = 0 (blue curve) or [B] = 100 (red curve). On each graph a marks the concentration of A at which the lower asymptote of the curve
in the presence of B intersects the curve in its absence, b and c mark the concentrations of A at which the curves cross, and d marks the
concentration of A at which the upper asymptote of the curve in the presence of B intersects the curve in its absence. Note it is only possible to
define a meaningful DR when b  [A]  c. For a < [A] < b and c < [A] < d the DR is in the opposite sense and when [A] < a or [A] > d a DR
cannot be defined (and equation (A2) gives a negative value). The vertical black lines mark the upper and lower bounds on the range of [A]
derived in Hall (2013) where [A] has little effect on the DR. (A) The modulator is an agonist with positive activation cooperativity and negative
binding cooperativity. The parameters for this simulation were: Ka = 10, Kb = 10, a = 50, eA = 100, eB = 2, eAB = 400, v = 0.1, n = 1. (B) The
modulator is an inverse agonist with neutral activation cooperativity and positive-binding cooperativity. The parameters for this simulation were:
Ka = 10, Kb = 10, a = 0.03, eA = 100, eB = 0.3, eAB = 30, v = 0.1, n = 1.
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one allosteric ligand case, the pharmacological stimulus,
S, can be defined as:
S ¼ ½R þ eA½AR þ eB½BR þ eC½CR þ eAB½ARB
þ eAC½ARC:
Again, let the response be given by
where v = [R]T/Ke. Note that when [A] = 0, equa-
tion (A3) simplifies to the following
E ¼
Emaxvn 1þ eB½BKb þ
eC ½C
Kc
 n
1þ ½BKb þ
½C
Kc
 n
þvn 1þ eB½BKb þ
eC ½C
Kc
 n
which is simply the equation describing the functional
effects of two ligands competing at the same binding site
(as expected). Also, when [A] ≫ Ka, that is the orthosteric
ligand is close to saturating the receptor, equation (A3)
simplifies to the following
E ¼
EmaxvnenA 1þ eAB½BeAaKb þ
eAC ½C
eAbKc
 n
1þ ½BaKb þ
½C
bKc
 n
þvnenA 1þ eAB½BeAaKb þ
eAC ½C
eAbKc
 n (A4)
If one of the allosteric ligands is present at a much
higher concentration than that of the other, for example
let eAB[B]/aKb ≫ eAC[C]/bKc, then this simplifies to the
following
E ¼ Emaxv
nenAB
1þ vnenAB
showing that the effect of one allosteric ligand on the
maximal response to A can dominate that of the other at
a sufficiently high concentration. This is consistent with
our expectation of competing ligands.
The DR in the presence of two allosteric ligands
which bind to the same site on the receptor can be
determined in a similar way to that described in Sec-
tion 1a:
Equating responses to equieffective concentrations of
orthosteric ligand in the presence and absence of the
modulators and rearranging gives equation (A5).
This has a similar linear rational structure to A2 with
additive contributions from the two ligands. It is also
consistent with the expectation that the effects of one
modulator can overwhelm those of another with which it
competes if a sufficiently high concentration is used. For
ranges of orthosteric ligand concentration where the con-
centration-response curves in the absence and presence of
the allosteric ligands are approximately parallel, this sim-
plifies to the following
E ¼ EmaxS
n
Kne þ Sn
¼ Emax ½R þ eA½AR þ eB½BR þ eC½CR þ eAB½ARB þ eAC½ARCð Þ
n
Kne þ ½R þ eA½AR þ eB½BR þ eC½CR þ eAB½ARB þ eAC½ARCð Þn
¼
Emaxvn 1þ eB½BKb þ
eC ½C
Kc
þ eA½AKa 1þ
eAB½B
eAaKb
þ eAC ½CeAbKc
  n
1þ ½BKb þ
½C
Kc
þ ½AKa 1þ
½B
aKb
þ ½CbKc
  n
þvn 1þ eB½BKb þ
eC ½C
Kc
þ eA½AKa 1þ
eAB½B
eAaKb
þ eAC ½CeAbKc
  n (A3)
Emaxvn 1þ eA½AKa
 n
1þ ½AKa
 n
þvn 1þ eA½AKa
 n
¼
Emaxvn 1þ eB½BKb þ
eC ½C
Kc
þ eA½A0Ka 1þ
eAB½B
eAaKb
þ eAC ½CeAbKc
  n
1þ ½BKb þ
½C
Kc
þ ½A0Ka 1þ
½B
aKb
þ ½CbKc
  n
þvn 1þ eB½BKb þ
eC ½C
Kc
þ eA½A0Ka 1þ
eAB½B
eAaKb
þ eAC ½CeAbKc
  n
DR ¼
1þ ½BKb
eAeB
eA1 þ Ka½A 1eBeA1
 
þ ½CKc eAeCeA1 þ Ka½A 1eCeA1
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
þ ½CbKc
eAC1
eA1 þ
½A
Ka
eACeA
eA1
  (A5)
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DR ¼
1þ ½BKb
eAeB
eA1
 
þ ½CKc
eAeC
eA1
 
1þ ½BaKb
eAB1
eA1
 
þ ½CbKc eAC1eA1
 
Equation (A5) then allows the derivation of the key
result of this section for the interpretation of modulator
combination experiments which is that, except under cer-
tain conditions noted below, DRBC ≤ DRB + DRC (where
the subscript indicates the ligand(s) whose DR is being
quantified). That is, the DRs of two allosteric ligands act-
ing at the same site are maximally additive. To see this,
note that if each term is positive,
1
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
þ ½CbKc
eAC1
eA1 þ
½A
Ka
eACeA
eA1
 
\
1
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
As this inequality is also true of any common multiple of
both sides, and hence of each other term in equation (A5)
(compared to an appropriate form of equation A2),
DRBC ≤ DRB + DRC follows:
1þ ½BKb
eAeB
eA1 þ
Ka
½A
1eB
eA1
 
þ ½CKc
eAeC
eA1 þ
Ka
½A
1eC
eA1
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
þ ½CbKc eAC1eA1 þ
½A
Ka
eACeA
eA1
 

1þ ½BKb
eAeB
eA1 þ
Ka
½A
1eB
eA1
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
þ
1þ ½CKc
eAeC
eA1 þ
Ka
½A
1eC
eA1
 
1þ ½CbKc
eAC1
eA1 þ
½A
Ka
eACeA
eA1
 
It is only possible for the DRs to be supraadditive (i.e.,
for DRBC to be greater than DRB + DRC) if either or both
of the variable terms in the denominator of equation (A5)
is negative, while leaving the denominator itself positive.
Assuming that eA > 1 (i.e., A is an agonist), this supraaddi-
tivity could only be true for all concentrations of A if
eAB ≤ 1 or eAC ≤ 1, that is, if A is no longer an agonist
when B or C is bound to the receptor. If 1 < eAB < eA, then
DRBC > DRB + DRC when [A] > Ka(eAB – 1)/(eA – eAB)
(and similarly for C). That is if either allosteric ligand con-
verts A into a partial agonist, the concentration-ratios
become supraadditive above some concentration of A.
Thus, supraadditivity of concentration-ratios is possible
but only if one or both of the allosteric modulators reduce
the maximal response to A. The effects of coincubation are
approximately additive when the denominator of A5 is
approximately unity, that is when the terms in [B] and [C]
in the denominator are both much less than unity or the
effect of one cancels the effect of the other. In the former
case, the behaviour is equivalent to that of the combination
of two competitive antagonists.
Amodel of the effects of two allosteric
ligands which bind to distinct allosteric sites
Now consider the case of two allosteric modulators that
bind to distinct binding sites on the receptor. The reac-
tion scheme for this is shown in Figure A1B (again, see
Hall 2006). The equilibrium concentration of the free
receptor is given by the following:
½R ¼ ½RT
1þ ½AKa þ
½B
Kb
þ ½CKc þ
½A½B
aKaKb
þ ½A½CbKaKc þ
½B½C
cKbKc
þ ½A½B½CabcdKaKbKc
where, Ka, Kb, and Kc are the equilibrium dissociation con-
stants of A, B, and C, respectively, and a and b are the binding
cooperativity constants of A with B and C, respectively, c is
the binding cooperativity of B with C and d is the higher
order cooperativity constant for the binding of one of the
ligands when the other two are bound to the receptor. The
concentrations of the other receptor species can be obtained
from this expression by multiplying [R]T in the numerator
by: [A]/Ka for [AR]; [B]/Kb for [BR]; [C]/Kc for [CR]; [A][B]/
aKaKb for [ARB]; [A][C]/bKaKc for [ARC]; [B][C]/cKbKc
for [RBC]; or [A][B][C]/abcdKaKbKc for [ARBC]. In
this case we define the pharmacological stimulus as S =
[R] + eA[AR] + eB[BR] + eC[CR] + eAB[ARB] + eAC[ARC] +
eBC[RBC] + eABC[ARBC], and proceed as previously,
E¼ EmaxS
n
Kne þSn
¼ Emax ½Rþ eA½ARþ eB½BRþ eC½CRþ eAB½ARBþ eAC½ARCþ eBC½RBCþ eABC½ARBCð Þ
n
Kne þ ½Rþ eA½ARþ eB½BRþ eC½CRþ eAB½ARBþ eAC½ARCþ eBC½RBCþ eABC½ARBCð Þn
¼
Emaxvn 1þ eB½BKb þ
eC ½C
Kc
þ eBC ½B½CcKbKc þ
eA½A
Ka
1þ eAB½BeAaKbþ
eAC ½C
eAbKc
þ eABC ½B½CeAabcdKbKc
  n
1þ½BKbþ
½C
Kc
þ ½B½CcKbKcþ
½A
Ka
1þ ½BaKbþ
½C
bKc
þ ½B½CabcdKbKc
  n
þvn 1þ eB½BKb þ
eC ½C
Kc
þ eBC ½B½CcKbKc þ
eA½A
Ka
1þ eAB½BeAaKbþ
eAC ½C
eAbKc
þ eABC ½B½CeAabcdKbKc
  n (A6)
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When [A] = 0, the response is given by the following
E ¼
Emaxvn 1þ eB½BKb þ
eC ½C
Kc
þ eBC ½B½CcKbKc
 n
1þ ½BKb þ
½C
Kc
þ ½B½CcKbKc
 n
þvn 1þ eB½BKb þ
eC ½C
Kc
þ eBC ½B½CcKbKc
 n
which is, of course, identical to equation (A1) as the sys-
tem then reduces to that of two ligands interacting allos-
terically. When [A] ≫ Ka, the response is as follows
In this case, the terms in [B][C] prevent the effects of
high concentrations of one allosteric ligand on the maxi-
mal response to the orthosteric ligand from necessarily
overwhelming the effects of the other.
Equating the response to equieffective concentrations
of A in the presence and absence of both B and C gives
the following
When the terms in [A] can be neglected equation (A7)
simplifies to
DR ¼
1þ ½BKb
eAeB
eA1
 
þ ½CKc
eAeC
eA1
 
þ ½B½CcKbKc
eAeBC
eA1
 
1þ ½BaKb
eAB1
eA1
 
þ ½CbKc
eAC1
eA1
 
þ ½B½CabcdKbKc
eABC1
eA1
 
Equation (A7) contains terms in [B][C] and hence the
effects of one modulator cannot overwhelm those of the
other unless these “cross terms” are rendered insignifi-
cant (e.g., due to strong negative cooperativity between
B and C). Indeed, the structure of A7 indicates that, for
at least some combinations of the parameters, the
numerator and denominator will factorize, that is that
the interaction is inherently multiplicative. This is further
justified below and some special cases are derived, in
particular, justifying the choice of a surmountable
allosteric modulator as a “standard” for interaction
studies. However, as for any two real numbers w and z,
say, which are greater than 2, wz > w + z, this implies
that the DRs of allosteric modulators that act at different
sites will be supraadditive unless they exhibit (strong)
negative-binding cooperativity. This provides the
required contrast between the behaviour of modulators
acting at the same site (in general DRs maximally
additive) and those acting at different sites (likely to be
supraadditive).
Returning to the structure of equation (A7), the
numerator and denominator will factorize if the coeffi-
cients of [B][C] are the products of the coefficients of
[B] and [C] {(1 + ax)(1 + by) = (1 + ax + by + abxy)}.
Requiring this of the numerator gives the following
Emaxvn 1þ eA½AKa
 n
1þ ½AKa
 n
þvn 1þ eA½AKa
 n ¼ Emaxv
n 1þ eB½BKb þ
eC ½C
Kc
þ eBC ½B½CcKbKc þ
eA½A0
Ka
1þ eAB½BeAaKb þ
eAC ½C
eAbKc
þ eABC ½B½CeAabcdKbKc
  n
1þ ½BKb þ
½C
Kc
þ ½B½CcKbKc þ
½A0
Ka
1þ ½BaKb þ
½C
bKc
þ ½B½CabcdKbKc
  n
þ
vn 1þ eB½BKb þ
eC ½C
Kc
þ eBC ½B½CcKbKc þ
eA½A0
Ka
1þ eAB½BeAaKb þ
eAC ½C
eAbKc
þ eABC ½B½CeAabcdKbKc
  n
DR ¼
1þ ½BKb
eAeB
eA1 þ Ka½A 1eBeA1
 
þ ½CKc eAeCeA1 þ Ka½A 1eCeA1
 
þ ½B½CcKbKc
eAeBC
eA1 þ Ka½A 1eBCeA1
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
þ ½CbKc
eAC1
eA1 þ
½A
Ka
eACeA
eA1
 
þ ½B½CabcdKbKc
eABC1
eA1 þ
½A
Ka
eABCeA
eA1
  (A7)
E ¼
EmaxvnenA 1þ eAB½BeAaKb þ
eAC ½C
eAbKc
þ eABC ½B½CeAabcdKbKc
 n
1þ ½BaKb þ
½C
bKc
þ ½B½CabcdKbKc
 n
þvnenA 1þ eAB½BeAaKb þ
eAC ½C
eAbKc
þ eABC ½B½CeAabcdKbKc
 n
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which provides the following set of simultaneous equa-
tions (by “equating coefficients”).
c eA  eBð Þ eA  eCð Þ ¼ eA  eBCð Þ eA  1ð Þ ðaÞ
c eA  eBð Þ 1 eCð Þ þ eA  eCð Þ 1 eBð Þð Þ
¼ eA  1ð Þ 1 eBCð Þ ðbÞ
c 1 eBð Þ 1 eCð Þ ¼ 0 ðcÞ
(c) gives eB = 1 or eC = 1 (c = 0 is excluded as physically
meaningless). Letting eB = 1, (a) gives c eA  1ð Þ
eA  eCð Þ ¼ eA  eBCð Þ eA  1ð Þ and hence eBC ¼ eA  c
eA  eCð Þ and (b) gives c eA  1ð Þ 1 eCð Þ ¼ eA  1ð Þ
1 eBCð Þ from which eBC ¼ 1 c 1 eCð Þ. Thus,
1 c 1 eCð Þ ¼ eA  c eA  eCð Þ
eA  1 ¼ c eA  eC  1þ eCð Þ
c ¼ 1
which then gives eBC = eC. Similarly, if we assume eC = 1,
then we obtain c = 1 and eBC = eB. Requiring the same
of the denominator gives the following
This gives the following set of simultaneous equations
cd eAB  1ð Þ eAC  1ð Þ ¼ eA  1ð Þ eABC  1ð Þ ðdÞ
cd eAB  eAð Þ eAC  1ð Þ þ eAC  eAð Þ eAB  1ð Þð Þ
¼ eABC  eAð Þ eA  1ð Þ ðeÞ
cd eAB  eAð Þ eAC  eAð Þ ¼ 0 ðfÞ
(f) gives eAB = eA or eAC = eA. Letting eAB = eA, (d) gives
cd eAC  1ð Þ ¼ eABC  1ð Þandhence eABC ¼ 1þ cd eAC  1ð Þ
and(e)giveseABC ¼ eA þ cd eAC  eAð Þ. Hence,
1þ cd eAC  1ð Þ ¼ eA þ cd eAC  eAð Þ
eA  1 ¼ cd eAC  1 eAC þ eAð Þ
cd ¼ 1
from which eABC = eAC. Similarly, if eAC = eA, then cd = 1
and eABC = eAB.
The following conditions for the numerator and
denominator to factorize have been derived: c = d = 1,
eB = 1 and eBC = eC and/or eC = 1 and eBC = eB and
eAB  1
eA  1 þ
½A
Ka
eAB  eA
eA  1
 
eAC  1
eA  1 þ
½A
Ka
eAC  eA
eA  1
 
¼ 1
cd
eABC  1
eA  1 þ
½A
Ka
eABC  eA
eA  1
 
cd eAB  1þ ½A
Ka
eAB  eAð Þ
 
eAC  1þ ½A
Ka
eAC  eAð Þ
 
¼ eA  1ð Þ eABC  1þ ½A
Ka
eABC  eAð Þ
 
cd eAB  1ð Þ eAC  1ð Þ þ cd ½A
Ka
eAB  eAð Þ eAC  1ð Þ þ eAC  eAð Þ eAB  1ð Þð Þ
þ cd ½A
2
K2a
eAB  eAð Þ eAC  eAð Þ ¼ eA  1ð Þ eABC  1ð Þ þ ½A
Ka
eABC  eAð Þ eA  1ð Þ
eA  eB
eA  1 þ
Ka
½A
1 eB
eA  1
 
eA  eC
eA  1 þ
Ka
½A
1 eC
eA  1
 
¼ 1
c
eA  eBC
eA  1 þ
Ka
½A
1 eBC
eA  1
 
c eA  eB þ Ka½A 1 eBð Þ
 
eA  eC þ Ka½A 1 eCð Þ
 
¼ eA  1ð Þ eA  eBC þ Ka½A 1 eBCð Þ
 
c eA  eBð Þ eA  eCð Þ þ c Ka½A eA  eBð Þ 1 eCð Þ þ eA  eCð Þ 1 eBð Þð Þ
þ c K
2
a
½A2 1 eBð Þ 1 eCð Þ ¼ eA  eBCð Þ eA  1ð Þ þ
Ka
½A eA  1ð Þ 1 eBCð Þ
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eAB = eA and eABC = eAC and/or eAC = eA and eABC = eAB.
For example, let c = d = 1, eB = 1, eBC = eC, eAC = eA
and eABC = eAB, then A7 becomes
Restating this pharmacologically, the interaction
between two allosteric modulators which bind to distinct
binding sites is perfectly multiplicative if: the modulators
exhibit no binding or activation cooperativity with each
other, there is no higher order cooperativity, at least one
of the modulators is a neutral antagonist and at most one
of them exhibits activation cooperativity with the orthos-
teric ligand. Negative and positive cooperativity between
the modulators will result in sub- and supramultiplicative
interactions respectively.
Comparison of the effects on the maximal
response to the orthosteric ligand
It can also be instructive to consider the effects of the
combination of allosteric modulators on the maximal
response to the orthosteric ligand, particularly when at
least one of the orthosteric ligands, B say, is surmount-
able. In this case, the maximal response of a curve in the
presence of two competing allosteric modulators must lie
between that of the control curve and that of the curve in
the presence of the insurmountable (or suprasurmount-
able) modulator alone (the mathematical details are
shown below). If the allosteric ligands bind to different
sites this need not be the case, thus should the maximal
effect in the presence of the combination fall outside this
range, the modulators must bind to distinct sites. Also, it
is important to note that the converse is not true: it can-
not be assumed that an interaction between modulators is
competitive if the maximal response in their combined
presence lies between those in their presence individually.
Let the two modulators compete for the same site and
assume that B is surmountable then, eAB = eA (to a rea-
sonable approximation) and the expression for the maxi-
mal response to A (equation A4) becomes
E ¼
EmaxvnenA 1þ ½BaKb þ
eAC ½C
eAbKc
 n
1þ ½BaKb þ
½C
bKc
 n
þvnenA 1þ ½BaKb þ
eAC ½C
eAbKc
 n
It is necessary to define a condition under which the
maximal response in the presence of B and C is less than
that in the presence of C alone, that is
That is C must be suprasurmountable. Thus, when C is
insurmountable the maximal response to A in the pres-
ence of both allosteric ligands must be greater than that
in the presence of C alone. Indeed, whether C is insur-
mountable or suprasurmountable, if a surmountable
modulator competes with it then the maximal response
in the presence of the combination will lie between those
in the presence of the modulators individually.
DR ¼
1þ ½BKb þ
½C
Kc
eAeC
eA1 þ Ka½A 1eCeA1
 
þ ½B½CKbKc
eAeC
eA1 þ Ka½A 1eCeA1
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
þ ½CbKc þ
½B½C
abKbKc
eAB1
eA1 þ
½A
Ka
eABeA
eA1
 
¼
1þ ½BKb
 
1þ ½BaKb
eAB1
eA1 þ
½A
Ka
eABeA
eA1
  	 1þ
½C
Kc
eAeC
eA1 þ Ka½A 1eCeA1
  
1þ ½CbKc
 
EmaxvnenA 1þ ½BaKb þ
eAC ½C
eAbKc
 n
1þ ½BaKb þ
½C
bKc
 n
þvnenA 1þ ½BaKb þ
eAC ½C
eAbKc
 n\ Emaxv
nenA 1þ eAC ½CeAbKc
 n
1þ ½CbKc
 n
þvnenA 1þ eAC ½CeAbKc
 n
1þ ½C
bKc
 
1þ ½B
aKb
þ eAC½C
eAbKc
 
\ 1þ eAC½C
eAbKc
 
1þ ½B
aKb
þ ½C
bKc
 
1þ ½B
aKb
þ eAC½C
eAbKc
þ ½C
bKc
þ ½B½C
abKbKc
þ eAC½C
2
eAb
2K2c
\1þ ½B
aKb
þ ½C
bKc
þ eAC½C
eAbKc
þ eAC½B½C
eAabKbKc
þ eAC½C
2
eAb
2K2c
eA\eAC
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Apparent nonreciprocal effects
of allosteric modulators on agonist
binding in the ternary complex
model
As Andrews et al. (2008) showed previously and we
describe in this report, low-molecular weight CCR4
antagonists can inhibit agonist binding while CCL22 and
CCL17 do not inhibit the binding of the antagonists. This
appears to violate the principle of microscopic reversibil-
ity (Weber 1975) which requires that the effect of the
allosteric ligand or orthosteric ligand on the other’s affin-
ity is the same (which then allows the unambiguous defi-
nition of a thermodynamic constant {the cooperativity
constant} which quantifies the interaction). However, as
shown below, this behaviour is in fact consistent with the
predictions of the ternary complex model of G-protein
activation for an allosteric interaction. The model under
consideration is shown in Figure A3. The expression for
the binding isotherm for this model when neither recep-
tor nor G-protein is in excess was derived in Hall (2006).
It is only in this form that the model exhibits both high-
and low-affinity binding for agonists and inverse agonists.
It is then instructive to consider ligands which exhibit no
binding cooperativity (i.e., c = 1). If we denote the radio-
ligand by A and the inhibitor by B, then the binding iso-
therm under this assumption is given by equation (A8).
where,
R is the receptor, G is the G-protein, K and M are the
association equilibrium constants of ligands A and B,
respectively, a and b are their respective intrinsic activi-
ties, d is their activation cooperativity and L is the affinity
of free R for G.
In this case, the two ligands can only influence each
other’s binding through their effects on the binding of
the G-protein. This is most clearly demonstrated if we
consider the forms of equation (A8) when [G]T = 0 and
when [G]T ? ∞. In the former case, [G] = 0 and
Bound A ¼ K½A½RT 1þM½Bð Þ
1þM½B þ K½A 1þM½Bð Þ ¼
K½A½RT
1þ K½A
(A9)
In the latter case, [G]  [G]T and
Bound A¼ aKL½A½GT ½RT 1þ bdM½Bð Þ
L½GT þ bLM½B½GT þ aKL½A½GT 1þ bdM½Bð Þ
¼ aK½A½RT 1þ bdM½Bð Þ
1þ bM½B þ aK½A 1þ bdM½Bð Þ
(A10)
Thus, the allosteric ligand only affects the binding of
the orthosteric ligand (and vice versa) to RG complexes
and has no effect on the binding to free R. A little care is
required in the interpretation of A10 as it suggests that
binding to RG would not be influenced by a ligand with
no activation cooperativity (d = 1). However, this is an
“artefact” of allowing [G]T to become arbitrarily large
and hence saturate the receptor irrespective of the binding
affinity. This is not the case for finite [G]T. An agonist
radioligand has high affinity for the RG complex and
labels it selectively, if it has high efficacy. An inverse ago-
nist allosteric ligand (b  1) or one with strong negative
Bound A ¼ K½A½RT 1þ aL½G þM½B 1þ abdL½Gð Þð Þ
1þ L½G þM½B 1þ bL½Gð Þ þ K½A 1þ aL½G þM½B 1þ abdL½Gð Þð Þ (A8)
½G ¼  1þ K½Að Þ 1þM½Bð Þ
2L 1þ bM½B þ aK½A 1þ bdM½Bð Þð Þ þ
½RT  ½GT
 
2
 
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ K½Að Þ 1þM½Bð Þ
2L 1þ bM½B þ aK½A 1þ bdM½Bð Þð Þ þ
½RT  ½GT
 
2
 2
þ ½GT 1þ K½Að Þ 1þM½Bð Þ
L 1þ bM½B þ aK½A 1þ bdM½Bð Þð Þ
s
Figure A3. The ternary complex model of G-protein coupled
receptor activity with an allosteric modulator. Equilibrium constants
are defined in the text.
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activation cooperativity (d  1) can then affect the bind-
ing of the radioligand. However, an inverse agonist radio-
ligand has high affinity for free R and will label this form
of the receptor selectively. An allosteric agonist would
then only inhibit the binding of the radioligand from the
small proportion of RG complexes to which it binds.
Thus, the ternary complex model actually predicts that
there can be apparent nonreciprocal effects in binding
assays if the effects of agonists and inverse agonists are
compared using radioligands with different pharmacologi-
cal properties. The above behaviours are illustrated in Fig-
ure A4.
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Figure A4. Simulations using equation (A8) of the effects of (A) an inverse agonist on the high-affinity or low-affinity binding of an agonist
radioligand or (B) the effect of an agonist on the binding of an inverse agonist radioligand. For (A) the values of the parameters were: [R]T = 10,
[G]T = 0.5, K = 1, L = 0.001, M = 100, a = 10
5, b = 0.0001, d = 1. The radioligand was present at its apparent affinity for the high- (0.001) and
low-(1) affinity sites, respectively, in this simulation. For (B) the values of the parameters were: [R]T = 10, [G]T = 0.5, K = 100, L = 0.001, M = 1,
a = 0.0001, b = 105, d = 1. The concentration of the radioligand was 1 in this simulation.
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